公开(公告)号：US08969592B2

公开(公告)日：2015-03-03

申请号：US13347305

申请日：2012-01-10

Applicant: Bin Ma

Inventor： Bin Ma

IPC: C07D495/14 ,  C07D495/04 ,  C07F7/10 ,  C07F7/08

CPC classification number: C07D495/04 ,  C07D495/14 ,  C07F7/0812 ,  H01L51/0054 ,  H01L51/0071 ,  H01L51/0072 ,  H01L51/0074 ,  H01L51/0085 ,  H01L51/0094 ,  H01L51/5012 ,  H01L51/5016 ,  H01L51/5096

Abstract: Novel heterocyclic materials are disclosed. The materials contain a fused tetracyclic structure that can improve the properties of OLED devices when the novel heterocyclic materials are incorporated into such devices.

Abstract translation: 公开了新型杂环材料。 这些材料含有融合的四环结构，当将新的杂环材料并入这些器件时，可以改善OLED器件的性能。

公开(公告)号：US20150005300A1

公开(公告)日：2015-01-01

申请号：US14210277

申请日：2014-03-13

Applicant: FLATLEY DISCOVERY LAB

Inventor： BRIDGET M. COLE ,  RICHARD A. NUGENT ,  ANDREW KOLODZIEJ ,  KAREN HANDLEY ,  YEVGEN BARSUKOV

IPC: C07D498/04 ,  A61K31/502 ,  C07D401/04 ,  C07D403/04 ,  A61K31/506 ,  C07D405/04 ,  C07D401/12 ,  C07D401/14 ,  C07D401/06 ,  C07D487/04 ,  A61K31/519 ,  C07D405/14 ,  C07D413/12 ,  C07D405/12 ,  C07D413/14 ,  C07D519/00 ,  C07D417/14 ,  A61K31/5377 ,  C07D495/14 ,  A61K45/06 ,  C07D237/32

CPC classification number: C07D413/12 ,  A61K31/38 ,  A61K31/4245 ,  A61K31/443 ,  A61K31/47 ,  A61K31/502 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  A61K45/06 ,  C07D237/32 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D405/04 ,  C07D405/12 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D487/04 ,  C07D495/14 ,  C07D498/04 ,  C07D519/00 ,  A61K2300/00

Abstract: The invention relates to a compound of having the following formulae and methods of treating cystic fibrosis:

Abstract translation: 本发明涉及具有治疗囊性纤维化的下列通式和方法的化合物：

公开(公告)号：US20140371225A1

公开(公告)日：2014-12-18

申请号：US14210273

申请日：2014-03-13

Applicant: FLATLEY DISCOVERY LAB

Inventor： Bridget M. Cole ,  Richard A. Nugent ,  Andrew Kolodziej ,  Karen Handley ,  Yevgen Barsukov

IPC: C07D237/32 ,  A61K45/06 ,  C07D401/04 ,  C07D405/04 ,  C07D405/12 ,  A61K31/519 ,  C07D401/06 ,  C07D487/04 ,  A61K31/5025 ,  C07D413/12 ,  A61K31/506 ,  A61K31/502 ,  C07D405/14

CPC classification number: C07D413/12 ,  A61K31/38 ,  A61K31/4245 ,  A61K31/443 ,  A61K31/47 ,  A61K31/502 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  A61K45/06 ,  C07D237/32 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D405/04 ,  C07D405/12 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D487/04 ,  C07D495/14 ,  C07D498/04 ,  C07D519/00 ,  A61K2300/00

Abstract: The invention relates to a compound of Formula I and methods of treating cystic fibrosis comprising the step of administering a therapeutically effective amount of a compound of Formula I to a patient in need thereof:

Abstract translation: 本发明涉及式I化合物和治疗囊性纤维化的方法，其包括向有需要的患者施用治疗有效量的式I化合物的步骤：

公开(公告)号：US08895963B2

公开(公告)日：2014-11-25

申请号：US13138976

申请日：2010-05-11

Applicant: Ken-ichi Nakayama ,  Junji Kido ,  Yong-Jin Pu ,  Yohei Hashimoto ,  Naomi Oguma ,  Naoki Hirata

Inventor： Ken-ichi Nakayama ,  Junji Kido ,  Yong-Jin Pu ,  Yohei Hashimoto ,  Naomi Oguma ,  Naoki Hirata

IPC: H01L51/54 ,  C07D409/14 ,  H01L51/00 ,  C07D495/04 ,  C07D495/14 ,  C07D209/48

CPC classification number: C07D209/48 ,  C07D409/14 ,  C07D495/04 ,  C07D495/14 ,  H01L51/0053 ,  H01L51/0068 ,  H01L51/0074

Abstract: An organic semiconductor material is represented by the following formula (F):wherein A represents a cyclic conjugated skeleton structure formed of one or more aromatic rings, and R1 and R2 each independently represent a substituted or unsubstituted alkyl group. The organic semiconductor material has high electron mobility and high on/off ratio, and can form an organic semiconductor thin film by a solution process making use of its solution.

Abstract translation: 有机半导体材料由下式（F）表示：其中A表示由一个或多个芳环形成的环状共轭骨架结构，R 1和R 2各自独立地表示取代或未取代的烷基。 有机半导体材料具有高电子迁移率和高开/关比，并且可以通过使用其溶液的溶液法形成有机半导体薄膜。

公开(公告)号：US08853679B2

公开(公告)日：2014-10-07

申请号：US13387020

申请日：2010-08-05

Applicant: Sheena Zuberi ,  Tania Zuberi

Inventor： Sheena Zuberi ,  Tania Zuberi

IPC: H01L29/12

CPC classification number: C07D495/04 ,  C07D495/14 ,  C07D495/22 ,  C07F7/0816 ,  H01L51/0074 ,  H01L51/0545

Abstract: A semiconducting compound comprising the structure: where R1 to R4 independently comprise, but are not limited to, optionally substituted straight, branched or cyclic alkyl chains having 2 to 20 (e.g. 2 to 12) carbon atoms, alkoxy, amino, amido, silyl, alkyl, alkenyl, aryl or hetero aryl; where X1 and X2 independently comprise S, O, NR5 or SiR6R7 where R8 to R7 independently comprise C1 to C5 branched, straight or cyclic alkyl chains; and where Ar1 comprises a heterocyclic ring, and where n is an integer between 1 and 4.

Abstract translation: 包含以下结构的半导体化合物：其中R 1至R 4独立地包括但不限于任选取代的具有2至20（例如2至12）个碳原子的直链，支链或环状烷基链，烷氧基，氨基，酰胺基，甲硅烷基， 烷基，烯基，芳基或杂芳基; 其中X1和X2独立地包含S，O，NR5或SiR6R7，其中R8至R7独立地包含C1至C5支链的直链或环状烷基链; 并且其中Ar 1包含杂环，并且其中n是1和4之间的整数。

公开(公告)号：US08846762B2

公开(公告)日：2014-09-30

申请号：US13738846

申请日：2013-01-10

Applicant: Genentech, Inc. ,  F. Hoffmann—La Roche AG

Inventor： Steven Do ,  Richard Goldsmith ,  Tim Heffron ,  Aleksandr Kolesnikov ,  Steven Staben ,  Alan G. Olivero ,  Michael Siu ,  Daniel P. Sutherlin ,  Bing-Yan Zhu ,  Paul Goldsmith ,  Tracy Bayliss ,  Adrian Folkes ,  Neil Pegg

IPC: A01N37/00 ,  C07D333/00 ,  A61K31/4365 ,  A61K31/4196 ,  A61K31/53 ,  C07D495/04 ,  A61K31/496 ,  A61K31/427 ,  A61K31/429 ,  A61K31/4155 ,  C07D495/14 ,  A61K31/4245 ,  A61K31/4436 ,  C07D513/14 ,  A61K31/381

CPC classification number: C07F5/02 ,  A61K31/381 ,  A61K31/4155 ,  A61K31/4196 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/429 ,  A61K31/4365 ,  A61K31/4436 ,  A61K31/496 ,  A61K31/53 ,  C07D495/04 ,  C07D495/14 ,  C07D513/14

Abstract: Benzopyran and benzoxepin compounds of Formulas I and II, and including stereoisomers, geometric isomers, tautomer solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formulas I and II for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Abstract translation: 式I和II的苯并吡喃和苯并氧杂环己酮化合物，包括立体异构体，几何异构体，互变异构体溶剂合物，代谢物和药学上可接受的盐，可用于抑制脂质激酶，包括p110α和PI3K的其他同种型，并用于治疗疾病如癌症介导 通过脂质激酶。 公开了使用式I和II的化合物在体外，原位和体内诊断，预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。

公开(公告)号：US08835476B2

公开(公告)日：2014-09-16

申请号：US11909636

申请日：2006-03-06

Applicant: Fan Wu ,  Donald Weaver ,  Chris Barden ,  Christopher McMaster ,  David Byers ,  Annette Henneberry ,  Fuqiang Ban

Inventor： Fan Wu ,  Donald Weaver ,  Chris Barden ,  Christopher McMaster ,  David Byers ,  Annette Henneberry ,  Fuqiang Ban

IPC: A01N43/64 ,  A61K31/41 ,  A01N43/06 ,  A61K31/38 ,  C07D257/04 ,  C07D257/10 ,  C07D403/00 ,  C07D487/00 ,  C07D333/02 ,  C07D409/00 ,  C12Q1/18 ,  C07D495/14 ,  C07D409/04 ,  C07D409/14

CPC classification number: C12Q1/18 ,  A61K31/41 ,  C07D409/04 ,  C07D409/14 ,  C07D495/14 ,  Y02A50/473 ,  Y02A50/475 ,  Y02A50/478 ,  Y02A50/481

Abstract: The synthesis and activity of novel LpxA inhibitors is described, these inhibitors present antibacterial activity. The compounds were designed based on a receptor model developed using the crystal structure of LpxA and are arranged to have a favorable binding interaction at the active site of the enzyme. In particular, the compounds present the following formula (I) where V, W, X, Y and Z can be independently C, S, N or O and P1, P2 and P3 are ligands to bind to the three points of the proposed pharmacophore model. They can be chosen from a variety of groups.

Abstract translation: 描述了新型LpxA抑制剂的合成和活性，这些抑制剂具有抗菌活性。 基于使用LpxA的晶体结构开发的受体模型设计化合物，并且被设置为在酶的活性位点具有有利的结合相互作用。 特别地，化合物呈现下式（I）其中V，W，X，Y和Z可以独立地为C，S，N或O，并且P1，P2和P3是与所提出的药效团的三个点结合的配体 模型。 他们可以从各种团体中选出。

公开(公告)号：US20140243320A1

公开(公告)日：2014-08-28

申请号：US14232160

申请日：2012-07-12

Applicant: Takahiro Honda ,  Hiroshi Enomoto ,  Kenji Kawashima ,  Shinji Takaoka ,  Yasutaka Fujioka ,  Mamoru Matsuda ,  Koji Ohashi ,  Yukie Fujita ,  Shin-ichiro Hirai ,  Hiroaki Kurashima

Inventor： Takahiro Honda ,  Hiroshi Enomoto ,  Kenji Kawashima ,  Shinji Takaoka ,  Yasutaka Fujioka ,  Mamoru Matsuda ,  Koji Ohashi ,  Yukie Fujita ,  Shin-ichiro Hirai ,  Hiroaki Kurashima

IPC: C07D487/06 ,  C07D519/00 ,  C07D495/14

CPC classification number: C07D487/06 ,  A61K9/0048 ,  A61K9/0095 ,  A61K9/06 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/4858 ,  A61K9/4866 ,  A61K47/38 ,  C07D487/04 ,  C07D495/14 ,  C07D519/00

Abstract: A compound represented by the following general formula (1) or a salt thereof. R1 represents a halogen atom and so on; R2 and R3 each represent a hydrogen atom and so on; R4 and R5 each represent a hydrogen atom and so on, or R4 and R5 may form an oxo group; Ra and Rb each represent a lower alkyl group optionally having a substituent and so on, or they may bind to each other to form a nitrogen-containing heterocyclic ring which may be substituted by one or plural Rc; Rc represents an aryl group optionally having a substituent and so on; ring A represents a benzene ring and so on; and m represents 0, 1 or 2.

Abstract translation: 由下述通式（1）表示的化合物或其盐。 R1表示卤素原子等; R2和R3各自表示氢原子等; R4和R5各自表示氢原子等，或者R4和R5可以形成氧代基; Ra和Rb各自表示任选具有取代基等的低级烷基，或者它们可以彼此结合形成可被一个或多个R c取代的含氮杂环; Rc表示任选具有取代基的芳基等等; 环A代表苯环等; m表示0,1或2。

公开(公告)号：US20140209867A1

公开(公告)日：2014-07-31

申请号：US13823751

申请日：2013-01-29

Applicant: Qinghua Zou

Inventor： Qinghua Zou

IPC: H01L51/00

CPC classification number: H01L51/0074 ,  C07D495/14 ,  H01L51/001 ,  H01L51/0067 ,  H01L51/5012 ,  H01L51/5072

Abstract: The present invention provides a sulfonyl group-contained compound, organic electroluminescent device using the same, and a preparation method thereof. The sulfonyl group-contained compound is presented by the following formula: in which R1, R2, and R3 are alkyl groups, aromatic ring groups, —CN or —OCH3 and R1, R2, and R3 are linked in position 2 or 3 of benzene ring. The sulfonyl group-contained compound of the present invention combines three thiofluorenes to form a novel sulfonyl group-contained compound with dendrimer structure, which combines properties of electron affinity and electron transportation of thiofluorene and also combines dimension property of dendrimer structure. When the sulfonyl group-contained compound is used in a light-emitting layer or an electron transport layer of an organic electroluminescent device, the efficiency and the lifespan of the organic electroluminescent device can be increased.

Abstract translation: 本发明提供含磺酰基的化合物，使用该化合物的有机电致发光元件及其制备方法。 含有磺酰基的化合物由下式表示：其中R 1，R 2和R 3为烷基，芳环，-CN或-OCH 3，R 1，R 2和R 3在苯的2位或3位连接 环。 本发明的含磺酰基的化合物结合三种硫代芴以形成具有树枝状聚合物结构的新型含磺酰基的化合物，其结合了电子亲和力和硫芴的电子传递性质，并且还结合树枝状聚合物结构的尺寸性质。 当含有磺酰基的化合物用于有机电致发光器件的发光层或电子传输层时，可以提高有机电致发光器件的效率和寿命。

公开(公告)号：US20140171417A1

公开(公告)日：2014-06-19

申请号：US14109922

申请日：2013-12-17

Applicant: Mahbub AHMED ,  Alexander ASHALL-KELLY ,  Louisa GUERITZ ,  Jeffrey MCKENNA ,  Joseph MCKENNA ,  Simon MUTTON ,  Rakesh PARMAR ,  Jon SHEPHERD ,  Paul WRIGHT

Inventor： Mahbub AHMED ,  Alexander ASHALL-KELLY ,  Louisa GUERITZ ,  Jeffrey MCKENNA ,  Joseph MCKENNA ,  Simon MUTTON ,  Rakesh PARMAR ,  Jon SHEPHERD ,  Paul WRIGHT

IPC: C07D513/00 ,  C07D471/14 ,  A61K45/06 ,  C07D487/14 ,  A61K31/55 ,  A61K31/542 ,  A61K31/519

CPC classification number: C07D513/14 ,  A61K31/519 ,  A61K31/542 ,  A61K31/55 ,  A61K45/06 ,  C07D471/14 ,  C07D487/04 ,  C07D487/14 ,  C07D487/22 ,  C07D495/14 ,  C07D513/00

Abstract: The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof; and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.